Mike Wheatcroft

Chief Scientist

Astex Pharmaceuticals

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mike Wheatcroft is the Chief Scientist at Telix Pharmaceuticals in Australia. His research interests focus on targeted radionuclide therapy, particularly in the context of immune checkpoint inhibition and imaging of somatostatin positive tumors. Recent articles authored by Dr. Wheatcroft explore the therapeutic efficacy of alpha therapy in renal cell carcinoma models and advancements in diagnostic imaging for prostate cancer.

Articles (6)

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Bart Smeets

Reseacher/Lecturer

HAN University of Applied Sciences

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mike Wheatcroft

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model.

Imaging Somatostatin Positive Tumors with Tyr<sup>3</sup>-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68

Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer

Therapeutic efficacy and tolerability of [225Ac]Ac-DOTA-hG250 targeted alpha therapy in a clear cell renal cell carcinoma mice model

First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers

Collaborators (1)

Bart Smeets

Make your next move.